Virax Biolabs Group Limited (VRAX)
| Market Cap | n/a |
| Revenue (ttm) | 109,820 |
| Net Income (ttm) | -859,943 |
| Shares Out | n/a |
| EPS (ttm) | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | n/a |
| Previous Close | n/a |
| Day's Range | n/a |
| 52-Week Range | n/a |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About VRAX
Virax Biolabs Group is a holding company incorporated with no material operations of its own. We conduct our substantial operations in the United Kingdom and Hong Kong with operating subsidiaries in Singapore, China and British Virgin Islands and have been operating since 2013. We are a global innovative biotechnology group that primarily engages in sales, distribution and marketing of diagnostics test kits and med-tech and Personal Protective Equipment products for the prevention, detection, diagnosis and risk management of viral diseases with...
Financial Performance
In 2020, VRAX's revenue was $123,820, an increase of 23.97% compared to the previous year's $99,876. Losses were -$672,915, -9.00% less than in 2019.
Financial StatementsNews
Virax Biolabs Group IPO Registration Document (F-1)
Virax Biolabs Group has filed to go public with an IPO on the NASDAQ.